Since the release of results from the Cardiac Arrhythmia Suppression Trial (CAST), trust in pharmacological prevention of sudden cardiac death has progressively reduced. The search for approaches alternative to antiarrhythmic agents for the prevention of ventricular arrhythmias has led to the current situation in which catheter ablation and the implantation of defibrillators are the leading tools of the arrhythmia specialist. Over the past decade, the rise of molecular biology has enlightened several areas of medicine, including cardiology, by providing a novel understanding of the physiology and substrates of different disease states. In this setting, it is hoped that the field of electrophysiology may be able to exploit such advancements for therapeutic purposes.
File in questo prodotto:
Non ci sono file associati a questo prodotto.